The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 06, 2021

Filed:

Feb. 12, 2020
Applicants:

Emory University, Atlanta, GA (US);

Children's Healthcare of Atlanta, Inc., Atlanta, GA (US);

Inventors:

Raymond F. Schinazi, Miami, FL (US);

Christina Gavegnano, Decatur, GA (US);

Assignees:

Emory University, Atlanta, GA (US);

Children's Healthcare of Atlanta, Inc., Atlanta, GA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); C07K 14/00 (2006.01); C07K 16/28 (2006.01); C07K 14/76 (2006.01); C07K 14/765 (2006.01); A61K 31/519 (2006.01); A61K 45/06 (2006.01); A61K 38/08 (2019.01); A61K 38/17 (2006.01); A61K 38/10 (2006.01); A61P 31/14 (2006.01); A61P 31/18 (2006.01);
U.S. Cl.
CPC ...
A61K 31/519 (2013.01); A61K 38/08 (2013.01); A61K 38/10 (2013.01); A61K 38/17 (2013.01); A61K 38/1709 (2013.01); A61K 45/06 (2013.01); A61P 31/14 (2018.01); A61P 31/18 (2018.01); C12N 2740/16034 (2013.01); Y02A 50/30 (2018.01);
Abstract

Compounds, compositions, and methods of treatment and prevention of HIV, including HIV-1 and HIV-2, Dengue, and Chikungunya infection are disclosed. The compounds are TREM-1 inhibitors. Combinations of these TREM-1 inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, JAK inhibitors, macrophage depleting agents, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV, Dengue, or Chikungunya virus in an infected patient.


Find Patent Forward Citations

Loading…